These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21073313)

  • 41. Group A streptococcus epidemiology and vaccine implications.
    Cohen-Poradosu R; Kasper DL
    Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050
    [No Abstract]   [Full Text] [Related]  

  • 42. Regulation of virulence gene expression in Streptococcus pyogenes: determinants of differential mRNA decay.
    Bugrysheva JV; Scott JR
    RNA Biol; 2010; 7(5):569-72. PubMed ID: 21037420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
    Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
    Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dissecting Streptococcus pyogenes interaction with human.
    Ijaz M; Ameen F; Alfoteih YA; Shamim S; Alshehri WA; Murtaza G
    Arch Microbiol; 2020 Oct; 202(8):2023-2032. PubMed ID: 32504132
    [TBL] [Abstract][Full Text] [Related]  

  • 45. M protein and hyaluronic acid capsule are essential for in vivo selection of covRS mutations characteristic of invasive serotype M1T1 group A Streptococcus.
    Cole JN; Pence MA; von Köckritz-Blickwede M; Hollands A; Gallo RL; Walker MJ; Nizet V
    mBio; 2010 Aug; 1(4):. PubMed ID: 20827373
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Group a streptococcal vaccine candidates: potential for the development of a human vaccine.
    Henningham A; Gillen CM; Walker MJ
    Curr Top Microbiol Immunol; 2013; 368():207-42. PubMed ID: 23250780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of extracellular GAPDH in Streptococcus pyogenes virulence.
    Seidler KA; Seidler NW
    Mo Med; 2013; 110(3):236-40. PubMed ID: 23829111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. T4 Pili Promote Colonization and Immune Evasion Phenotypes of Nonencapsulated M4 Streptococcus pyogenes.
    Chen YH; Li SH; Yang YC; Hsu SH; Nizet V; Chang YC
    mBio; 2020 Jul; 11(4):. PubMed ID: 32694142
    [No Abstract]   [Full Text] [Related]  

  • 49. Update on group A streptococcal vaccine development.
    Dale JB; Walker MJ
    Curr Opin Infect Dis; 2020 Jun; 33(3):244-250. PubMed ID: 32304470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification and characterization of an antigen I/II family protein produced by group A Streptococcus.
    Zhang S; Green NM; Sitkiewicz I; Lefebvre RB; Musser JM
    Infect Immun; 2006 Jul; 74(7):4200-13. PubMed ID: 16790795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Toxins and Superantigens of Group A Streptococci.
    Shannon BA; McCormick JK; Schlievert PM
    Microbiol Spectr; 2019 Jan; 7(1):. PubMed ID: 30737912
    [No Abstract]   [Full Text] [Related]  

  • 52. Growth phase-associated changes in the transcriptome and proteome of Streptococcus pyogenes.
    Chaussee MA; Dmitriev AV; Callegari EA; Chaussee MS
    Arch Microbiol; 2008 Jan; 189(1):27-41. PubMed ID: 17665172
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Group A
    Pancholi V
    Microbiol Spectr; 2019 Jan; 7(1):. PubMed ID: 30767846
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of the transcriptome of group A Streptococcus in mouse soft tissue infection.
    Graham MR; Virtaneva K; Porcella SF; Gardner DJ; Long RD; Welty DM; Barry WT; Johnson CA; Parkins LD; Wright FA; Musser JM
    Am J Pathol; 2006 Sep; 169(3):927-42. PubMed ID: 16936267
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Similar ability of FbaA with M protein to elicit protective immunity against group A streptococcus challenge in mice.
    Ma CQ; Li CH; Wang XR; Zeng RH; Yin XL; Feng HD; Wei L
    Cell Mol Immunol; 2009 Feb; 6(1):73-7. PubMed ID: 19254483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Group A Streptococcus infections in children: from virulence to clinical management.
    Botteaux A; Budnik I; Smeesters PR
    Curr Opin Infect Dis; 2018 Jun; 31(3):224-230. PubMed ID: 29601325
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Group A streptococcal vaccines.
    Pichichero ME
    JAMA; 2004 Aug; 292(6):738-9. PubMed ID: 15304473
    [No Abstract]   [Full Text] [Related]  

  • 58. Inactivation of DltA modulates virulence factor expression in Streptococcus pyogenes.
    Cox KH; Ruiz-Bustos E; Courtney HS; Dale JB; Pence MA; Nizet V; Aziz RK; Gerling I; Price SM; Hasty DL
    PLoS One; 2009; 4(4):e5366. PubMed ID: 19401780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
    Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
    J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glucose Levels Alter the Mga Virulence Regulon in the Group A Streptococcus.
    Valdes KM; Sundar GS; Belew AT; Islam E; El-Sayed NM; Le Breton Y; McIver KS
    Sci Rep; 2018 Mar; 8(1):4971. PubMed ID: 29563558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.